Skip to content
Phoenix Biotechnology, IncPhoenix Biotechnology, Inc
  • Home
  • About Us
    • Company
    • Management Team
    • Boards Of Directors
    • Scientific Advisory Board
  • Therapy Focus
    • Therapy Focus
    • Viral Diseases
    • Cancer
    • Neurodegenerative Diseases
  • Product Development
    • Products in Development
    • PBI-05204
    • PBI-01207
    • PBI-04711
  • Safety
  • Resources
  • Contact us
Oleander

Phoenix Biotechnology, Inc. executes a share exchange agreement with Nerium Biotechnology, Inc. by which Nerium Biotechnology acquires all the Latin American operations of Phoenix.

Posted on December 2006June 2022 by Carlos Torres
06
Dec
This entry was posted in Oleander. Bookmark the permalink.
Publication: Oleandrin-mediated oxidative stress in human melanoma cells. Newman RA, Yang P, Hittelman WN, Lu T, Ho DH, Ni D, Chan D, Vijjeswarapu M, Cartwright C, Dixon S, Felix E, Addington C. J Exp Ther Oncol. 2006;5(3):167-81.
Phoenix enters into contract with Quintiles, Inc. to act as Clinical Research Organization for “An Open Label Phase I Trial of PBI-05204 in Advanced Cancer Patients” to be conducted at M. D. Anderson Cancer Center.
Copyright 2023 © Phoenix Biotechnology, Inc. All Rights Reserved. | Terms of Use | Privacy Policy | Cookies Policy
  • Home
  • About Us
    • Company
    • Management Team
    • Boards Of Directors
    • Scientific Advisory Board
  • Therapy Focus
    • Therapy Focus
    • Viral Diseases
    • Cancer
    • Neurodegenerative Diseases
  • Product Development
    • Products in Development
    • PBI-05204
    • PBI-01207
    • PBI-04711
  • Safety
  • Resources
  • Contact us